In the past week, IMMX stock has gone down by -14.04%, with a monthly decline of -30.10% and a quarterly plunge of -37.65%. The volatility ratio for the week is 8.63%, and the volatility levels for the last 30 days are 11.58% for Immix Biopharma Inc The simple moving average for the last 20 days is -11.71% for IMMX’s stock, with a simple moving average of -42.65% for the last 200 days.
Is It Worth Investing in Immix Biopharma Inc (NASDAQ: IMMX) Right Now?
Moreover, the 36-month beta value for IMMX is 0.22. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMMX is 13.85M and currently, short sellers hold a 2.80% of that float. On May 10, 2024, IMMX’s average trading volume was 186.59K shares.
IMMX) stock’s latest price update
Immix Biopharma Inc (NASDAQ: IMMX) has experienced a decline in its stock price by -7.34 compared to its previous closing price of 2.18. However, the company has seen a fall of -14.04% in its stock price over the last five trading days. Seeking Alpha reported 2023-12-03 that Immix Biopharma is a biotech company focused on developing CAR-T and other cell-based therapies for cancers and heme disorders. Their most advanced project is NXC-201, a BCMA-targeted CAR-T natural killer cell therapy, which has shown a 95% overall response rate in patients with multiple myeloma. They also have a tissue-specific platform called iMX-110, which is being assessed in early-stage studies for sarcoma and colorectal cancer.
IMMX Trading at -26.34% from the 50-Day Moving Average
After a stumble in the market that brought IMMX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.94% of loss for the given period.
Volatility was left at 11.58%, however, over the last 30 days, the volatility rate increased by 8.63%, as shares sank -24.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.76% lower at present.
During the last 5 trading sessions, IMMX fell by -11.28%, which changed the moving average for the period of 200-days by +2.21% in comparison to the 20-day moving average, which settled at $2.25. In addition, Immix Biopharma Inc saw -70.81% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMMX starting from Hsu Jason, who purchase 31,000 shares at the price of $4.67 back on Dec 11 ’23. After this action, Hsu Jason now owns 813,000 shares of Immix Biopharma Inc, valued at $144,894 using the latest closing price.
Hsu Jason, the Director of Immix Biopharma Inc, purchase 25,000 shares at $4.88 during a trade that took place back on Dec 08 ’23, which means that Hsu Jason is holding 782,000 shares at $122,025 based on the most recent closing price.
Stock Fundamentals for IMMX
Current profitability levels for the company are sitting at:
- -4014.03 for the present operating margin
- -0.04 for the gross margin
The net margin for Immix Biopharma Inc stands at -3805.47. The total capital return value is set at -0.67. Equity return is now at value -104.35, with -88.57 for asset returns.
Based on Immix Biopharma Inc (IMMX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -11.99. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -415.11.
Currently, EBITDA for the company is -16.13 million with net debt to EBITDA at 1.49. When we switch over and look at the enterprise to sales, we see a ratio of 5303.98. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.32.
Conclusion
To wrap up, the performance of Immix Biopharma Inc (IMMX) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
